All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
On Tuesday 26 March 2019, Oral Session 4 (OS4) took place at the 45th Annual Meeting of the European Society of Blood and Marrow Transplantation (EBMT), Frankfurt, DE. During that session, Abstract OS4-1 was presented by Leyre Bento from Son Espases University Hospital, Palma de Mallorca, SP.
This presentation provided results of a retrospective study from the Lymphoma Working Party (LWP) and EBMT, regarding the efficacy and safety of tandem autologous-reduced intensity allogeneic stem cell transplantation (auto-RIC allo-SCT) in high-risk relapsed or refractory (R/R) Hodgkin lymphoma (HL). The primary endpoint of the study was progression-free survival (PFS) after auto-RIC-allo-SCT. Secondary endpoints included overall survival (OS), cumulative incidence of non-relapse mortality (NRM), incidence of relapse (IR) and graft-versus-host disease (GvHD).
Outcome |
Variable |
---|---|
Decreased PFS
|
Female patient Not in CR at auto-/allo-SCT |
Increased cumulative IR |
Female patient Not in CR at auto-/allo-SCT |
Decreased engraftment |
Total body irradiation (TBI) before allo-SCT Cord blood |
Increased acute GvHD |
Unrelated donors |
Increased chronic GvHD |
Thymoglobulin-based conditioning Female donor |
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox